Maria Kolesnikova

Dr. Maria Kolesnikova

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MKMaria Kolesnikova
Maria Kolesnikova
ASAleksandra V. Sen'kova
Aleksandra V. Sen'kova
STSofia Tairova
Sofia Tairova
VOViktor Ovchinnikov
Viktor Ovchinnikov
TPTatiana Pospelova
Tatiana Pospelova
MZMarina Zenkova
Marina Zenkova
Multidrug resistance (MDR) is a major challenge in leukemia treatment. The objective of this study was to identity predictors of MDR to allow for rapid and economical assessment of the efficacy of planned antitumor therapy for leukemia patients. The study included 113 patients with acute and chronic leukemias. Prior to antitumor therapy, we measured the sensitivity of tumor cells of patients to the panel of chemotherapeutic drugs, together with MDR1 mRNA and P-glycoprotein (P-gp) expression as one of the mechanisms of MDR, and compared these data with the response to therapy. The scales for leukemia patients according to therapy response, drug sensitivity of tumor cells, MDR1 mRNA and P-gp levels, and the presence of unfavorable immunological and cytogenetic markers were introduced for subsequent correlation analysis. We show that the drug resistance of tumor cells of leukemia patients estimated in vitro at diagnosis correlates with a poor response to chemotherapy and is usually combined with aberrant and immature immunological markers, cytogenetic abnormalities, and a high expression of MDR1 mRNA and P-gp. All together, these factors indicate unfavorable prognosis and low survival of leukemia patients. Thus, the sensitivity of tumor cells to chemotherapeutic drugs measured in vitro at diagnosis may have prognostic value for individual types of leukemia.

29 May 2022 in Revista Amazonia Investiga
Verified
Journal Article
Open access
VSVolodymyr Sukhonos
Volodymyr Sukhonos
VPVolodymyr Pakhomov
Volodymyr Pakhomov
VPViktoriia Pylypenko
Viktoriia Pylypenko
MKMaria Kolesnikova
Maria Kolesnikova
DMDmytro Maletov
Dmytro Maletov
The article is devoted to an important and modern topic of studying the administrative and legal framework for the implementation of e-government in Ukraine. Its relevance is due to the fact that Ukraine, as a developing country, has quite high rating of the United Nations e-Government Development Index. Therefore, the existence of an appropriate legal framework and an extensive system of public authorities that are actors in the field of e-government is a priority issue. The purpose of this article is to determine the components of the administrative and legal framework for the implementation of e-government in Ukraine. The object of this article is public relations to implement and operate e-government. The subject of the study is directly the administrative and legal principles of implementation in Ukraine. The authors propose to analyze the concept of e-government in Ukraine, its potential to address a range of issues, and the risks of its improper implementation. Methods which were used for proper research: method of terminological analysis, structural-functional method, descriptive, institutional approach, critical-dialectical and legal analysis methods.

6 March 2021 in Cancer Reports
Verified
Journal Article
Open access
PDF file
MKMaria Kolesnikova
Maria Kolesnikova
ASAleksandra V. Sen'KOva
Aleksandra V. Sen'KOva
TPTatiana I. Pospelova
Tatiana I. Pospelova
MZMarina Zenkova
Marina Zenkova
Background: Acute myeloid leukemia (AML) is the most common acute leukemia in adults, and chemotherapy remains the most commonly used treatment approach for this group of hematological disorders. Drug resistance is one of the predictors of unfavorable prognosis for leukemia patients.Aim: The purpose of this study was to perform a retrospective analysis of the survival rate in AML patients according to age, tumor status, and chemotherapy regimen received and to analyze the therapy response of AML patients depending on the treatment received, initial responsiveness of tumor cells to chemotherapeutic drugs measured in vitro at diagnosis and expression of immunological markers.Methods: The survival of AML patients (n = 127) was analyzed using the Kaplan‐Meier method. Drug sensitivity of tumor cells of AML patients (n = 37) and the expression of immunological markers were evaluated by the WST test and flow cytometry, respectively. Correlation analysis was performed using Spearman's rank order correlation coefficient.Results: We found the treatment regimen to be the defining factor in the patient survival rate. In addition, the initial responsiveness of tumor cells to chemotherapeutic drugs measured in vitro at diagnosis correlated with the therapy response of AML: patients with high tumor cell sensitivity to particular cytotoxic drugs demonstrated a good response to treatment including these drugs, and patients with initial resistance of tumor cells to a particular chemotherapeutic agents and received it according to the clinical protocols demonstrated a poor response to antitumor therapy. Correlations of drug resistance in leukemic cells with the expression of immature and aberrant immunophenotype markers as established unfavorable prognostic factors confirm our assumption.Conclusion: The evaluation of the responsiveness of tumor cells to chemotherapy in vitro at diagnosis can be a useful tool for predicting the response of leukemia patients to planned chemotherapy.

Verified
Journal Article
Open access
PDF file
MKMaria Kolesnikova
Maria Kolesnikova
ASAleksandra V. Sen'kova
Aleksandra V. Sen'kova
TPTatiana I. Pospelova
Tatiana I. Pospelova
MZMarina Zenkova
Marina Zenkova
Acute myeloid leukemia (AML) is a hematopoietic disorder characterized by the malignant transformation of bone marrow-derived myeloid progenitor cells with extremely short survival. To select the optimal treatment options and predict the response to therapy, the stratification of AML patients into risk groups based on genetic factors along with clinical characteristics is carried out. Despite this thorough approach, the therapy response and disease outcome for a particular patient with AML depends on several patient- and tumor-associated factors. Among these, tumor cell resistance to chemotherapeutic agents represents one of the main obstacles for improving survival outcomes in AML patients. In our study, a new prognostic scale for the risk stratification of AML patients based on the detection of the sensitivity or resistance of tumor cells to chemotherapeutic drugs in vitro as well as MDR1 mRNA/P-glycoprotein expression, tumor origin (primary or secondary), cytogenetic abnormalities, and aberrant immunophenotype was developed. This study included 53 patients diagnosed with AML. Patients who received intensive or non-intensive induction therapy were analyzed separately. Using correlation, ROC, and Cox regression analyses, we show that the risk stratification of AML patients in accordance with the developed prognostic scale correlates well with the response to therapy and represents an independent predictive factor for the overall survival of patients with newly diagnosed AML.

6 March 2021 in Siberian journal of oncology
Verified
Journal Article
Open access
PDF file
EVElena Voropaeva
Elena Voropaeva
AGA. A. Gurageva
A. A. Gurageva
TPT. I. Pospelova
T. I. Pospelova
MKMaria Kolesnikova
Maria Kolesnikova
MVMikhail Voevoda
Mikhail Voevoda
EME. V. Melnichenko
E. V. Melnichenko
Background. The annual reporting forms for malignant neoplasms do not provide for the division of lymphomas into variants. In international publications and statistical reference books of the Russian Federation, variants of non-Hodgkin’s lymphomas (NHL) are also not separated. For these reasons, a detailed assessment of the epidemiology of NHL in Russia is difficult, and data for individual variants of the disease are not provided.Purpose: to present the clinical and epidemiological characteristics of Diffuse Large B-cell Lymphoma (DL BCL ) in Novosibirsk according to the data of the City Hematology Center (CHC).Material and Methods. A retrospective analysis of primary medical documentation (case histories, outpatient charts, and immunohistochemical study reports) of 271 patients with DL BCL was performed in the period from January 1, 2013 to December 31, 2018.Results. The calculated registered primary morbidity and mortality from DL BCL in Novosibirsk for the analyzed years fluctuated slightly. The average incidence and mortality rates were 2.85 and 1.98 per 100,000 population, respectively. When analyzing the dynamics of the prevalence of DL BCL in Novosibirsk, a positive trend of annual increase in the indicator was revealed: 1.87 times over the past 6 years. In men, the tumor developed 2.6 years earlier than in women. In General, the risk of getting DL BCL after 50 years was 3 times higher than at the age of 30 years. Among patients diagnosed with primary lymphoma who underwent treatment at the Hematology department of CHC, half of the patients had DL BCL .Evaluation of the clinical characteristics showed a pronounced severity of the analyzed cohort.Conclusion. The updated quantitative and qualitative indicators of clinical and epidemiological characteristics of DL BCL in Novosibirsk for 2013–18 were obtained. These indicators can be used for further monitoring, development and implementation of measures for the prevention, diagnosis and treatment of this form of hemoblastosis.

30 June 2019 in HemaSphere
Verified
Journal Article
Open access
EVElena Voropaeva
Elena Voropaeva
TPT. Pospelova
T. Pospelova
MVMikhail Voevoda
Mikhail Voevoda
VMV. Maximov
V. Maximov
MKMaria Kolesnikova
Maria Kolesnikova
Background: Single nucleotide replacement rs78378222 lead to change of the normal TP53 gene polyadenylation signal and cause disorders of processing of 3′‐end of mRNA. The experimental data have suggested that rare allele C of the rs78378222 leads to much lower level of TP53 expression and decrease the apoptosis induction level in cells under the influence of genotoxic agents in comparison with allele A. Thus, rs78378222 is thought to be the unique allele variant of TP53 gene with the reduced p53 function.Aims: The purpose of the present study was to reveal the frequency of the rs78378222 of TP53 in tumor tissue of the patients with diffuse large B‐cell lymphoma (DLBCL).Methods: Genomic DNA was isolated from formalin‐embedded paraffin blocks of lymph nodes and extranodal tumor lesions biopsies of 92 patients with DLBCL by phenol‐chloroform extraction method using guanidine. The tissue sections containing at least 70‐80% of the tumor cells were taken. Genotyping of the rs78378222 was performed by the PCR‐RFLP method. To confirm the presence of rare allele C of the rs78378222 Sanger's direct sequencing was performed.Results: The frequency of the rs78378222 in DLBCL tumor tissue was 9/92 (9.8%). It was noted that 5 of 9 patients had minor allele C in the homozygous state. Since the detection of cases of the rare homozygous genotype C/C of the rs78378222 in normal tissue has not described previously, the received results indicated a loss of heterozygosity in the TP53 gene in DLBCL tumor tissue of rs78378222 carriers. Only two of these cases were combined with mutations in the gene. In three cases ‐ loss of heterozygosity was the only aberration in TP53.Summary/Conclusion: Aberrations in 3′‐UTR of TP53 gene may be a universal carcinogenesis mechanism, playing role in pathogenesis of DLBCL as well. The loss of normal allele A rs78378222 stimulates the significant growth of cells malignant potential.